Psammiad Therapeutics
Denver, US · Founded 2022 · Delaware corporation
Biotech
Founders & leadership
MV
Matthew VeatchExecutive Officer
AG
Anthony GerberExecutive Officer, Director
ME
Michael EberExecutive Officer
Reported raises · per SEC filings
Form D private placements▶$2.2MraisedFeb 2022 · 5 investors · BiotechnologyRule 506(b)
Officers, directors & promoters on the filing
- Matthew VeatchExecutive Officer
- Anthony GerberExecutive Officer, Director
- Michael EberExecutive Officer
- Offering amount
- $3M
- Amount sold
- $2.2M
- Minimum investment
- $10K
- First sale
- Jan 2022
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.